Expanding Rare Disease Pipeline Will Open New Markets
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 11 Analysts
Published
09 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$16.73
48.8% undervalued intrinsic discount15 Aug
US$8.56
1Y
5.7%7D
2.3%